Rekord LOINC: 96603-6

Qualitative results for detection of neutralizing antibodies (NAbs) that block the binding of the S (spike) protein receptor binding domain (RDB) from SARS Coronavirus 2 (SARS-CoV-2) to ACE2 receptor protein in serum or plasma specimens by surrogate virus neutralization testing (sVNT), which is an immunoassay-based method. Neutralizing antibody testing is performed to determine whether the antibodies produced after SARS-CoV-2 infection or in response to a vaccination are able to neutralize the virus and prevent infection or re-infection. Different methods can be used to determine the presence of neutralizing antibodies, including conventional VNT (virus neutralization test, cVNT), pseudovirus VNT (pVNT), and surrogate VNT (sVNT). The sVNT method currently employs purified proteins in an immunoassay-based format, takes less time to complete, and does not require the use of live virus compared to cVNT and pVNT methods.

2019 Novel Coronavirus; 2019-nCoV; ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Corona virus; COVID19; COVID-19; ID; II; Infectious Disease; InfectiousDisease; Microbiology; NAb; Ordinal; Pl; Plasma; Plsm; Point in time; PR; Prot; QL; Qual; Qualitative; Random; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; SARS-CoV-2 S; SARS-CoV-2 S RBD; SARS-CoV-2 S RBD Nab; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; Severe Acute Respiratory Syndrome; SR; surrogate virus neutralization testing; sVNT; Viral Pneumonias; Wuhan coronavirus